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Abstract Objective A vulvar squamous intraepithelial lesion is deemed to be a preceding lesion
to vulvar cancer, especially in women aged under 40 years, holders of an acquired or
idiopathic immunosuppression. Several treatments have been used to treat these
lesions. One of the aesthetically acceptable therapeutic methods is the CO2 laser
vaporization.
Methods In a transversal study, 46 records of immunosuppressed women bearing a
vulvar low grade and/or high grade squamous intraepithelial lesion were selected out
of the retrospective analysis, computing age, date of record, date of vulvar lesion
treatment with CO2 laser, the time elapsed between the first and the last visit (in
months), the number of visits, the presence or absence of condylomatous lesions in
other female lower genital tract sites and whether or not recurrences and persistence
of intraepithelial lesions have been noticed during the follow-up.
Results Patients bearing vulvar high-grade squamous intraepithelial lesion and immu-
nosuppressed (serumpositive for human immunodeficiency virus [HIV]or with solid organs
transplantation) have shown a higher level of persistence of lesions and a higher chance of
having other areas of the female lower genital tract involved.
Conclusion While the CO2 laser vaporization is the most conservative method for the
treatment of vulvar high-grade intraepithelial lesions, it is far from being the ideal method,
due to the intrinsic infection features considered. Thepossibilityof persistence, recurrences
and spontaneous limited regression indicates that a closer surveillance in the long-term
treated cases should be considered, in special for immunosuppressed patients.
Resumo Objetivo A lesão intraepitelial escamosa da vulva é considerada uma lesão precursora
do câncer vulvar, em especial emmulheres com idade inferior a 40 anos, portadoras de
imunossupressão adquirida ou idiopática. Vários tratamentos têm sido utilizados para
received
July 27, 2017
accepted
November 30, 2017
DOI https://doi.org/
10.1055/s-0037-1618573.
ISSN 0100-7203.
Copyright © 2018 by Thieme Revinter
Publicações Ltda, Rio de Janeiro, Brazil
Original Article
THIEME
26
Introduction
Thevulvarhigh-gradesquamous intraepithelial lesion (VHSIL),
which was termed “vulvar intraepithelial neoplasia usual
type” in the 2004 International Society for the Study of
Vulvovaginal Disease (ISSVD) terminology, according to its
histopathological constitution in 60 to 100% of cases, is related
to the presence of the human papillomavirus (HPV), and it is
presented in multifocal form.1 The VHSIL adopts a clinical
aspect infection by HPV, with verrucous or plain lesions,
mainly in glabrous areas, its color varying from greyish-white
to brownish. Its incidence prevails among mature women, in
their third or fourth decades of life, being even higher in those
holding immunosuppression. The symptoms of VHSIL vary
from itching, burning, local discomfort, eventually ulceration
and bleeding. However, in most of cases, the patients are
symptom-free. These lesions have a discrete potential for
regression and can slowly evolve into an invasive cancer,
and their frequency is lower than the differentiated vulvar
intraepithelial neoplasia.1–4
The treatment of these lesions is indicated both to for pain
relief and to avoid the progression of the disease into an
invasive cancer. Since 1960, the radical vulvectomy was the
preferred treatment among the proposed ones. Upon the
recognition that this type of lesion presented a biological
behavior different from that of an invasive cancer, an option
was made for simple vulvectomy. The vulvar anatomy alter-
ation resulting from the surgery and thehigh recurrence rates,
from 30 to 60%, had influence on the search of lesions
destructive therapeutic methods, such as electrocoagulation,
cryocoagulation, application of chemical agents and immuno-
modulators. Also, the association of more than one method,
such asexcision, destructionorbothhasbeenused.4–7TheCO2
laser vaporization is the most conservative form among the
destructive methods. The CO2 laser produces electromagnetic
energy in the formofan infrared light issuedwithawavelength
of 10.6 µmwith an average power of 10 to 10,000W. The tissue
destruction results from the raised temperature of cellular
contents, transforming the intracellularwater into steam, thus
leading to cell lysis.Witha focusedbeam, theCO2 laser can also
make the excision of lesion. This fact permits the performance
of an anatomopathological exam, if necessary. The cure rate
after a vaporization session is of 76.9% of cases, rising up to
78.4% after 2 sessions. Complications are minimal and occur
only upon the improper use of themethod. Attention has been
brought to the high recurrence rates, which vary from 23 to
40% of cases.6–9
The objective of this study was to assess the share of cases
that show recurrences in immunosuppressed patients and,
in special, the recurrence of VHSIL after a CO2 vaporization
treatment; to assess whether the treatment with CO2 laser is
effective, and, finally, the occurrence of lesions in other
regions of the female lower genital tract regions.
Methods
In a transversal study, 46 records of patients attended at the
vulvaambulatory, in thesectorof lowergenital tract pathology
of a gynecologic diseases prevention center in the state of São
Paulo, Brazil, were retrospectively analyzed within the period
from January of 2002 to December of 2014. The project was
presented to the Research Ethics Committee of the institution
for analysis and was approved (CEP: 0040/2015; opinion:
1045864), and the current proposal is part of a larger project
called: Treatment of vulvar intraepithelial neoplasia with CO2
laser vaporization, developed by the same authors. The
tratar esse tipo de lesão. Um dos métodos terapêuticos esteticamente aceitáveis é a
vaporização a laser CO2.
Métodos Em um estudo transversal, foram selecionados da análise retrospectiva de
prontuários arquivados no setor de patologia do trato genital inferior 46 prontuários de
mulheres com imunossupressão e portadoras de lesão intraepitelial escamosa de baixo
grau e/ou alto grau computando-se: idade, data de registro, data do tratamento da
lesão vulvar com laser CO2, tempo entre a primeira e a última consulta (em meses),
número de consultas, presença ou ausência de lesões condilomatosas em outros locais
do aparelho reprodutor feminino e a ocorrência ou não de recidivas e persistência de
lesões intraepiteliais durante o período de acompanhamento.
Resultados Pacientes com lesão intraepitelial de alto grau vulvar e imunocompro-
metidas (soropositivas para HIV ou com transplante de órgãos sólidos) mostraram
maior índice de persistência das lesões e maior chance de ter outras áreas do órgão
genital feminino comprometidas.
Conclusão Embora a vaporização a laser CO2 seja o método mais conservador para o
tratamento das lesões intraepiteliais vulvares de alto grau, está longe de ser o método
ideal pelas características intrínsecas da afecção em foco. A possibilidade de persis-
tência, recidivas e regressão espontânea limitada recomenda maior vigilância para os
casos tratados a longo prazo, em especial para as pacientes com imunossupressão.
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patients signed a Deed of Free and Informed Consent upon the
therapeutic method proposal.
The selected patients were classified in accordance with
the following criteria: age, date of filing at the gynecological
diseases prevention center, date of vulvar lesion treatment
with CO2 laser, number of visits, presence of absence of
condylomatous lesions in other sites of the female lower
anogenital tract and what sites these were, the presence or
absence of lesion persistence or recurrences, and the number
of visits occurred. A convention was made to consider as
recurrence the appearance of a new lesion after 3 months
from the concluded treatment. Persistence would be charac-
terized by the detection of a new lesion since thefirst clinical
control, within 15 days after the treatment. An attempt was
made to demonstrate whether the treatment with CO2 laser
vaporization was effective; the type of prevalent lesion, and
whether they were more frequent in cases of immunosup-
pression and lesions in other regions of the female lower
anogenital tract.
The collected information was considered in two groups,
as follows: a) human immunodeficiency virus (HIV)þ: serum
positive patients, and b) SOT: patients with solid organ
transplantations. Each group was further subdivided into
two subgroups: vulvar low-grade squamous intraepithelial
lesion (VLSIL) and VHSIL.
The data were tabulated and submitted for statistical
analysis by a professional from the statistics service of a
university in São Paulo, Brazil.
The statistical analysis of all the information collected for
this research was initially performed in descriptive form,
through average, median, minimum and maximum values;
standard deviation, and absolute and relative frequencies
(percentage). The inferential analysis employedwith the aim
of confirming or rejecting the evidences found in the de-
scriptive analysis were:
– t-Student test for independent samples,10 or Mann-Whit-
ney test11 for the comparison of the subgroups: VLSIL and
VHSIL.
– Fisher Exact test extension12 for the study of the associa-
tion between the group of patients bearing virus-caused
HIVþ and patients submitted to SOT.
In all the conclusions reached out of the inferential
analysis, an α level of significance equal to 5% was utilized.
The information was typed in Excel 2010 Windows (Micro-
soft Corp., Redmond, WA, USA) forms for the proper storage
of information. The statistical analysis was performed
through the statistic software IBM SPSS Statistics for Win-
dows, version 19.0. (IBM Corp., Armonk, NY, USA)
Results
It was verified that, out of the 46 women exhibiting all the
research criteria, 17 (36.95%) patients had VLSIL, against 29
(63.04%) bearing VHSIL.
The VLSIL group comprised14womenbearingHIV þ infec-
tion and 3 patientswith SOT. Regarding thewomenpresenting
VHSIL, 16 were serum positive for HIV and 13 had SOT.
The average age among the patients with VLSIL and HIV
was 32.3 years (varying from 16 to 51 years) and among the
ones with VHSIL and HIV, it was 34.9 years (varying from 22
to 47 years). Patients bearing VLSIL and SOT, in turn, had an
average age of 29 years (16 to 38 years) and those bearing
VHSIL and SOT was 36.1 years, varying from 21 to 63 years.
The t-Student test assessment for independent samples and
the Mann-Whitney test assessment failed to show a statisti-
cally significant difference.
The patients bearing VLSIL and HIVþ presented a higher
numberofaffectedareas,with14women(46.79%)withupto3
or 4 affected areas. In respect to the VHSIL and HIVþ, 16 cases
(53.5%) showed up to 3 affected areas (p ¼ 0.077). An isolated
infection of the vulva occurred in 6 out of 16 patients with
VHSIL and HIVþ. The same happened to 5 out of 13 bearers of
VHSIL and SOT (►Table 1).
The application of the Mann-Whitney statistic test evi-
denced a trend for statistic difference just for the VHSIL and
HIVþ . By assessing the different time intervals correspond-
ing to the follow-up time of all patients, we found once again
a trend for higher significance among those bearing VHSIL, in
special those with HIV infection. Most of the patients with
VHSIL, both the HIV-serum positive and the transplanted
ones, came to 6– 10 visits after the CO2 laser vaporization,
during a variable time from 13 to 25 months (►Table 2).
Likewise, an attempt wasmade to compare whether differ-
ences would appear between the number of visits performed
by both groups, from the beginning of the treatment until the
last recorded notes. It was found that no difference appeared
among them, since most of the patients came to return visits
after the 19th visit and only one out of three patients bearing
organs transplantation and HSIL, with three patients, came
until the 48th.
Out of 16 patients bearing HIV and VHSIL, 12 cases (75%)
of lesions persistence after the treatment were computed.
The same occurred in 14 VLSIL and HIVþ patients, with only
Table 1 Distribution of 46 women bearing vulvar viral lesions
under the conditions of immunosuppression, association of
affected areas and intra- and intergroups statistical analysis
Association of affected areas
Vulva
n (%)
2 areas
n (%)
3 areas
n (%.)
4 areas
n (%)
Total
n (%)
HIVþ 30 (100.0)
VLSIL 2 (25.0) 1 (25.0) 10 (58.8) 1
(100.0)
14 (46.7)
VHSIL 6 (75.0) 3 (75.0) 7 (41.2) 0 (–) 16 (53.3)
SOT 16 (100.0)
VLSIL 0 (–) 1 (20.0) 2 (33.3) 0 (–) 3 (18.7)
VHSIL 5 (100.0) 4 (80.0) 4 (66.7) 0 (–) 13 (81.3)
Abbreviations: HIV þ , infection by the Human Immunodeficiency Virus;
n, number of cases; SOT, Solid organs transplantation; VLSIL, vulvar Low
Grade Squamous Intraepithelial Lesion; VHSIL, vulvar High-Grade
Squamous Intraepithelial Lesion.
Statistical analysis –HIVþ –VLSIL X VHSIL; p ¼ 0.077Mann-Whitney test;OT
–VLSILXVHSIL;p ¼ 0.239Mann-Whitney test;VLSIL–HIVþXOT;p ¼ 0.768
Mann-Whitney test; VHSIL HIVþ X OT; p ¼ 0.714 Mann-Whitney test.
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5 women (35.7%) showing persistence of lesions. Within the
group of patientswith SOT, a similar result was noticed. Only
three cases of recurrences were computed, with two of the
patients being HIVþ and one bearing SOT (►Table 3).
The exact Fisher test extension, excluding the cases with
no information, showed a statistically significant difference
as to the VHSIL cases persistence for HIVþ women.
Discussion
Variation of age and symptoms, type of intraepithelial lesion,
predominant location, psychological factors and,mainly, states
of immunosuppression cause patients with vulvar intraepi-
thelial lesions to receive different treatments. The possibility of
relapses is frequent, and the results depend on the best choice
decided in common agreement between patient and doctor.
It has been recommended that low-grade vulvar lesions
can only be followed-up or treated conservatively. When
there is a need for an active option, destructive, excisional or
immunomodulatory treatments may be used.
Because of the elevated potential for malignancy and a
higher probability of relapses or persistence, VHSIL deserve
greater attention and individualized decisions. Small lesions
can be excised easily in the outpatient setting, but multifocal
procedures require major care, such as hospitalization for
clinical and anesthetic attention. It is recommended that
destructive treatments always be performed after histopath-
ological examination that excludes invasion.
Chueri and Brito13 report amedical assistance protocol for
immunosuppressed patients using topical application of
fluorouracil 5%, twice a week, for four weeks, followed by
removal of the remaining lesions with CO2 laser vaporiza-
tion. Satisfactory responses occur in 75% of the cases. The use
of surgery with loops of high frequency waves, when in
extensive cases, needs to be performed at a surgical center
and can result in unpleasant and uncomfortable scars
depending on the extent of the lesions. On the other hand,
CO2 laser vaporization can be performed on an outpatient
basis, with topical anesthesia, inmore than one session.With
this procedure, remissions are reported in 75–80% of cases
and can reach 97% when a second procedure is performed.
Leufflen et al,14when comparing excisional treatmentwith
laser vaporization, described a remission rate of 91% after one
year with excisional treatment compared to 65% with laser
therapy.
In recent years, several authorshave suggested theuseof 5%
imiquimod, an immunomodulator with antiviral and antitu-
mor action. It increases the production of interleukin, inter-
feron and tumor necrosis factor. When applied on the lesion 3
times a week, at night, for 16 weeks, it allows complete
regression of lesions in 50 to 80% of cases. As with laser
Table 2 Distribution of 46 women bearing vulvar viral lesions, as per the immunosuppression conditions, the follow-up time gap,
intra- and intergroup statistical analysis
Follow up time interval in months
01 to 29
n (%)
30 to 59
n (%)
60 to 89
n (%)
90 or more
n (%)
No inf.
n (%)
Total
n (%)
HIVþ 30 (100.0)
VLSIL 10 (56.3) 1 (25.0) 0 (–) 0 (–) 3 (60.0) 14 (46.7)
VHSIL 7 (43.7) 3 (75.0) 1 (10.0) 3 (100.0) 2 (40.0) 16 (53.3)
SOT 16 (100.0)
VLSIL 2 (25.0) 0 (-) 0 (–) 0 (–) 1 (50.0) 3 (18.7)
VHSIL 6 (75.0) 2 (100.0) 1 (100.0) 3 (100.0) 1 (50.0) 13 (81.3)
Abbreviations: HIV þ , infection by the human immunodeficiency virus; n, number of cases; No Inf., no information; SOT, solid organs
transplantation; VLSIL, vulvar low grade squamous intraepithelial lesion; VHSIL, vulvar high-grade squamous intraepithelial lesion.
highest value 136 months - Statistical analysis: HIV (VLSIL X VHSIL) p ¼ 0.084 Mann-Whitney test excluding “no information” – OT (VLSIL X VHSIL)
p ¼ 0,352 Mann-Whitney test excluding “no information” – VLSIL (HIVþ X OT) p ¼ 0.909 Mann-Whitney test excluding “no information” – VHSIL
(HIVþ X OT) p ¼ 0.940 Mann-Whitney test excluding “no information.
Table 3 Distribution of 46 women bearing vulvar viral lesions
under theconditionsof immunosuppression in termsofpersistence
and/or recurrences number and intra- and intergroups statistical
analysis
Persistence and/or recurrence in numbers
Recurrence
n (%)
No of
lesions
n (%)
No inf.
n (%)
Total
n (%)
HIVþ 30 (100.0)
VLSIL 1 (50.0) 4 (100.0) 4 (57.11) 14 (46.7)
VHSIL 1 (50.0) 0 (–) 3 (42.9) 16 (53.3
SOT 16 (100.0)
VLSIL 0 (–) 1 (33.5) 1 (25.0) 3 (18.8)
VHSIL 1 (100.0) 2 (66.7) 3 (75.0) 13 (81.3)
Abbreviations: HIV þ : infection by the human immunodeficiency virus;
n: number of cases; No inf, No information; SOT, solid organs transplan-
tation; T, total number; VLSIL, vulvar low grade squamous intraepithelial
lesion; VHSIL: vulvar high-grade squamous intraepithelial lesion.
Statistical analysis: HIVþ (VLSIL X VHSIL) p ¼ 0.024 exact Fisher extent
excluding “no information” –OT; (VLSIL X VHSIL) p ¼ 0.576 exact Fisher
extent excluding “no information” – VLSIL (HIV X OT) p > 0.999 exact
Fisher Extent excluding “no information” - VHSIL (HIV X OT) p ¼ 0.413
exact Fisher extent excluding “no information.
Rev Bras Ginecol Obstet Vol. 40 No. 1/2018
Therapeutic Assessment of Vulvar Squamous Intraepithelial Lesions with CO2 Laser Vaporization Ribalta et al. 29
vaporization, there is functional and anatomical preservation
of the vulva.
For Rama et al,15 the clinical response was similar when
the treatments with imiquimod cream 5% and CO2 laser
vaporization were compared. No recurrent lesions, but a
statistical differencewas seenwhen the severity of recurrent
lesions was assessed. Upon the follow-up, the difference was
noted in the histological grade of the recurrent lesions
(p ¼ 0.048). The women submitted to the CO2 laser treat-
ment presented alterations with high histological grade,
while 83.3% of the patients treated with imiquimod 5%
presented lesions with lower severity.13–15
The induced immunosuppression, both by an HIV-in-
duced infection or by SOT or other diseases, predispose
patients bearing VLSIL and VHSIL to present more polymor-
phic lesions and persistent conditions, whatever the insti-
tuted treatments might be. A higher probability of evolution
to invasive neoplastic conditions results. Then, a constant
and extended clinical assessment is necessary. This informa-
tion coincides with those by Speck et al.8
The VHSIL patients, both HIV-serum positive and organs
transplanted, showed the widest age range compared with
the VLSIL patients, but with no statistical significance. Like-
wise, the infection in other areas in addition to the vulvawas
more notorious among women bearing VLSIL and HIVþ than
in the others. Thus, the importance of the proliferative
process of HPV-induced lesions in more extended areas is
featured, and on the other hand, the aggressiveness of
VHSILs, upon immunosuppression of whatever nature. The
same conclusion is shared by such authors as Speck et al,5
Parellada et al4 and Girardi et al.3
The follow-up after the CO2 laser application in VLSIL in
patients with immunosuppression, both by HIV-induced
infections or by SOT, such as kidneys and pancreas, in special,
evidenced that patients bearing VHSIL, of both groups, were
more concerned with not failing the control than the others,
despite all of them receiving the same return guidance.
The persistence of lesions after the CO2 laser vaporization
treatment appeared to be more evident among patients
bearing VHSIL and HIV, a fact that was also observed by
Penna et al7 and Speck et al.8 However, an evaluated sample
showed recurrence, that is, the reappearance of the lesion
after 3 months from the conclusion of the treatment — a
conventionally-established term — in only 3 cases, with two
of the patients being serum positive and one transplanted.
The short term considered for a recurrence or the lack of
return to be established, or the size of sample, or even the
lack of a proper catalogue of data might justify the low
recurrence index. Those conditions, bound to the frequent
persistence of lesions, induce the health professionals to
introduce a long-term post-operative adjuvant therapeutic
alternative, as suggested by Speck et al, in 2004.9
Conclusion
Patients who are immunosuppressed, due to HIV infection or
to SOT, andwho have an intraepithelial vulvar lesion, do it in a
more concerning form, as pre-neoplastic lesions throughout
the third and fourth decades of life; they are more resistant to
the laser destructive treatment and exhibit higher persistence
index. That fact, therefore, suggests the need of a deeper
surveillance in frequency and time gap, aiming to avoid a
possible clinical evolution toward an invading neoplasia.
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